Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Maxim Positive on Omeros' (OMER) Omidria, OMS721; Reaffirms at 'Buy'
March 8, 2016 12:21 PM ESTMaxim reaffirms Omeros (Nasdaq: OMER) at 'Buy' following Q4 results and initiation of its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome... More
Omeros (OMER) Tops Q4 Loss Per Share of 52c
March 7, 2016 5:26 PM ESTOmeros (NASDAQ: OMER) reported Q4 EPS of ($0.52), may not compare to analyst estimate of ($0.55). Revenue for the quarter came in at $6.66 million versus the consensus estimate of $5.35 million.
For earnings history and earnings-related data on Omeros (OMER) click here.
... More